Effects of CPAP on endothelial activation and fibrinolytic balance in coronary artery disease with obstructive sleep apnea: The RICCADSA randomized controlled trial.

Int J CardiolJul 31, 2026 (epub)
Clinical ResearchCardiologyPulmonology

Semih Arbatli, Tülay Yucel-Lindberg, Erik Thunström et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of CPAP therapy on endothelial activation and fibrinolytic balance in 210 patients with coronary artery disease (CAD) and obstructive sleep apnea (OSA). The study found that CPAP treatment significantly reduced VCAM-1 levels over time compared to no-CPAP (p = 0.045), indicating a selective modulation of vascular biomarkers.

Key findings

  • CPAP treatment led to a significant reduction in VCAM-1 levels over time compared to no-CPAP (p = 0.045).
  • No significant time-by-treatment interaction was observed for ICAM-1.
  • A borderline interaction suggested a smaller increase in PAI-1 in the CPAP group (p = 0.09).

Why it matters

Understanding the vascular effects of CPAP in patients with CAD and OSA is crucial, as it may help mitigate atherosclerotic progression and improve patient outcomes in this high-risk population.

Source

PubMed · PMID 42537929

Published in Int J Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.